In this episode, we delve into a new horizon in the management of acute agitation. We discuss dexmedetomidine, a drug that's been around since 1999, recently reformulated into a sublingual film and FDA approved for treating agitation associated with schizophrenia or bipolar I or II disorder. We explore the results from a recent randomized trial and its potential for transforming psychiatric care. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CMEs: Quick Take Vol. 47
• Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial